Scientists at Kaiser Permanente Washington Health Research Institute (KPWHRI) are on the forefront of efforts to understand, prevent, diagnose, and treat COVID-19. This includes vaccines, medications, forecasts, and impacts of the virus on various health conditions.
Vaccine trial registries
Vaccine safety monitoring
Studies now enrolling Kaiser Permanente Washington members
Research on COVID-19 risk factors and disparities
Other COVID-19 studies
Voluntary symptom reporting
KPWHRI builds on its background of longstanding participation as a Vaccine and Treatment Evaluation Unit and collaboration with the Centers for Disease Control and Prevention (CDC) and the National Institute of Allergy and Infectious Diseases (NIAID), among other partners, to help develop vaccines to prevent COVID-19. Our work includes the following:
On March 16, 2020, KPWHRI gave the world’s first-ever injection of an investigational vaccine for COVID-19 to volunteers in a phase 1 clinical trial led by Senior Investigator Lisa A. Jackson, MD, MPH.
The vaccine — which was co-developed by the National Institutes of Health (NIH) and Moderna Inc. — was well tolerated and generated an immune response that exceeded the average responses from a group of people recovering from the disease, according to a New England Journal of Medicine report on the phase 1 trial findings. After the trial was expanded to include adults 56 years and older, a second paper was published in the New England Journal of Medicine, reporting that the vaccine is well-tolerated and generated a strong immune response in older adults.
On July 27, 2020, a phase 3 trial was launched to test the effectiveness — and continue to test the safety — of the NIH-Moderna vaccine. KPWHRI is one of 100 locations in this ongoing trial. A review of the phase 3 data found that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults, with an efficacy rate of 94.1%.
Additional evidence of the vaccine’s benefits were reported Dec. 3, 2020, in a letter in the New England Journal of Medicine co-authored by Dr. Jackson. Based on data from the phase 1 clinical trial, investigators found that the vaccine continued to provide a significant immune response 119 days after first vaccination and 90 days after second vaccination in 34 healthy adults.
On the strength of these and other findings, the U.S. Food and Drug Administration approved an emergency use authorization of the NIH-Moderna vaccine on Dec. 18, 2020.
KPWHRI continues to monitor the people vaccinated in the phase 1 and phase 3 trials of this vaccine.
Janssen and HDT Bio Corp. vaccines
On Nov. 18, 2020, KPWHRI began enrolling volunteers in another phase 3 clinical trial to evaluate a COVID-19 vaccine made by Janssen Pharmaceutical Companies of Johnson & Johnson.
The team is also slated to collaborate with HDT Bio Corp. on a phase 1 clinical trial of the firm’s experimental COVID-19 vaccine.
Interested in volunteering for a COVID-19 vaccine trial? KPWHRI has established a registry to collect information from people in the Seattle area who want to participate in current and future trials. Previously, only adults 18 and older were eligible for this registry. In February 2021, the registry expanded to allow Seattle-area parents to add the names of children under age 18. Potential volunteers can contact the registry at corona.kpwashingtonresearch.org.
The COVID-19 Prevention Trials Network also has a volunteer screening registry of people nationwide who are interested in participating in a broader range of vaccines and other preventive therapies at various research facilities in Seattle and around the country: coronaviruspreventionnetwork.org.
KPWHRI researchers are working with the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, and colleagues in other KP regions and other health systems on projects that monitor the safety and effectiveness of the vaccines now being distributed to the general population. To learn more, see KP biostatisticians help monitor COVID-19 vaccine safety.
Kaiser Permanente Washington members may be contacted for possible participation in the following COVID-19 studies:
Self-Swab Respiratory Virus Study
KPWHRI researchers are contacting select patients who recently received care in person or virtually from a Kaiser Permanente Washington provider or who recently spoke with the Consulting Nurse Service about a cold or flu-like illness. When people agree to join the study, they are sent a kit to self-collect a swab that will be tested for SARS-CoV-2, flu, and other respiratory viruses. This allows researchers to explore how many people get sick with COVID-19, what kinds of symptoms they have, how risk varies across populations, and what factors increase risk of severe illness.
Stool test kit
KPWHRI and University of Washington researchers are collaborating to develop and evaluate a test kit to detect virus shed into stool. This study will start enrolling some patients at Kaiser Permanente Washington soon.
KPWHRI has launched a research project to evaluate risk factors for COVID-19 with Kaiser Permanente Colorado and Kaiser Permanente Northwest. The research collaboration follows a KPWHRI study, published in the American Journal of Hypertension, finding no association of use of ACEI/ARB medication with risk of COVID-19 infection or hospitalization. The multi-site effort, which is being supported by the Garfield Memorial Fund, includes 3 inquiries:
KPWHRI is a major contributor to understanding of the spread of COVID-19 in Washington state, because researchers have access to comprehensive information about a large real-world population. KPWHRI has also provided a variety of resources and support to the Kaiser Permanente Washington care-delivery system to help prevent, screen for, and treat COVID-19, such as:
In addition, the many Kaiser Permanente enrollees who participate in the Kaiser Permanente Research Bank are providing blood samples and medical information that will be useful in the organization's ongoing COVID-19 research nationally. The Research Bank has collected COVID-19 survey data on biobank participants that is available for research use.
Along with the research activities described above, Kaiser Permanente and the Permanente Medical Group are conducting a voluntary symptom tracking program focused on targeted prevention to stop the spread of COVID-19. The program aims to help Kaiser Permanente’s COVID-19 response teams to assess a large sample of Kaiser Permanente members, monitor the spread of the virus, and try to proactively curb the pandemic. The program staff is reaching out via email and/or SMS text to a random sample of Kaiser Permanente Washington members, inviting them to participate over a 2-month period. Although this program is not considered a research activity, the data collected will be used to track and predict the spread of the virus, catch clusters of the virus early, identify new outbreaks, and better prepare our medical staff and facilities for possible spikes in cases.
Kaiser Permanente Washington members can find information about testing, diagnosis, and treatment for COVID-19 here.
Kaiser Permanente Washington Health Research Institute
Kaiser Permanente Washington Health Research Institute
Dr. Sascha Dublin tells how studies of KP electronic health record data can improve COVID-19 treatment and prevention.
A registry started by KPWHRI last year has sped up studies needed to protect the world against the novel coronavirus.
The investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of about 94% as research continues.
Dr. Jennifer Nelson explains how KP scientists are helping the CDC and FDA keep an eye out for rare adverse events.
The institute is participating in NIAID tests of Moderna and Johnson & Johnson vaccines.
People, March 4, 2021